U.S. markets close in 3 hours 24 minutes
  • S&P 500

    3,347.31
    +48.85 (+1.48%)
     
  • Dow 30

    27,660.82
    +486.86 (+1.79%)
     
  • Nasdaq

    11,040.22
    +126.66 (+1.16%)
     
  • Russell 2000

    1,509.89
    +34.98 (+2.37%)
     
  • Crude Oil

    40.50
    +0.25 (+0.62%)
     
  • Gold

    1,878.60
    +12.30 (+0.66%)
     
  • Silver

    23.47
    +0.37 (+1.61%)
     
  • EUR/USD

    1.1656
    +0.0022 (+0.19%)
     
  • 10-Yr Bond

    0.6610
    +0.0020 (+0.30%)
     
  • GBP/USD

    1.2843
    +0.0099 (+0.78%)
     
  • USD/JPY

    105.5480
    +0.0020 (+0.00%)
     
  • BTC-USD

    10,897.41
    +118.60 (+1.10%)
     
  • CMC Crypto 200

    234.17
    +10.25 (+4.58%)
     
  • FTSE 100

    5,927.93
    +85.26 (+1.46%)
     
  • Nikkei 225

    23,511.62
    +307.00 (+1.32%)
     

BioCryst's immune disorder drug succeeds in mid-stage trial

May 27 (Reuters) - BioCryst Pharmaceuticals Inc said its experimental drug for treating a rare immune disorder was effective in reducing the attacks of the disease in a mid-stage trial.

The drug, BCX4161, was compared with a placebo and was being tested in patients with hereditary angioedema (HAE) - a genetic disease characterized by sudden attacks of swelling of the skin or the mucous membranes, which can be disfiguring, painful and life-threatening.

Those treated with the drug had an average rate of 0.82 attacks per week, compared with 1.27 for those given a placebo.

(Reporting by Esha Dey in Bangalore; Editing by Savio D'Souza)